Retinitis Pigmentosa
Conditions
Keywords
Retinitis Pigmentosa, Modifier Gene Therapy, Modified Gene Therapy, RHO, RP, NR2E3, Subretinal Injection
Brief summary
This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.
Detailed description
This expanded access protocol provides access to OCU400 for a subset of patients. Subjects will undergo specific ocular testing included in the study. Subjects will follow-up with physical examination, review of concomitant medication, blood work and ocular examinations for up to 52 weeks (about 12 months) post dosing.
Interventions
DRUGOCU400
Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
Sponsors
Ocugen
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Inclusion criteria
1. Males or females ≥18 years of age at the time of informed consent. 2. Confirmed clinical and CLIA certified genetic diagnosis of RP (except subjects with AD-NR2E3 mutation) 3. Presence of photoreceptors as determined by spectral-domain optical coherence tomography (SD-OCT).
Exclusion criteria
1. Subject lacks evidence of outer nuclear layer, i.e., containing the nuclei of the retinal photoreceptors as determined by SD- OCT. 2. Considered unsuitable for any reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes by the Investigator, or the Sponsor after reviewing the subject medical history and condition. 3. Previous treatment with a gene-therapy or cell therapy product, excluding OCU400. 4. Previous treatment with any investigational drug or device within one year, excluding OCU400. 5. Any contraindications for subretinal injection. 6. Cataract surgery within 3 months. YAG capsulotomy within 1 month. Any other intraocular surgery within 6 months
Countries
United States
Contacts
CONTACTUmair Qazi, MD, MPH
CONTACTSahar Matloob, MD
STUDY_DIRECTORJennifer Henrick, RN, MS
Ocugen., Inc.
STUDY_CHAIRMohamed Genead, MD
Ocugen., Inc
Outcome results
None listed